Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Jul 10, 2026
Direxion Daily Financial Bull 3X ETF (FAS) Delivers +20% Gains Over 30 Days on Financial Sector Strength

Direxion Daily Financial Bull 3X ETF (FAS) Delivers +20% Gains Over 30 Days on Financial Sector Strength

Key Takeaways

  • FAS surged approximately 20% over the last 30 days, driven by a powerful rally in U.S. financial stocks amplified by the fund's 3x daily leverage.
  • The quarterly trend is also strongly positive, with FAS gaining roughly 27% over the past three months.
  • Outsized contributions from top holdings — including JPM, BAC, GS, and BRK.B — have been central to the move.
  • Renewed investor confidence in the banking and capital markets segments, supported by a favorable interest rate backdrop, has propelled the underlying index higher.
  • As a leveraged ETF (Exchange-Traded Fund), FAS magnifies daily index returns and is designed for short-term trading, not buy-and-hold investing.

FAS ETF Overview and Its Concentrated Exposure to Financials

FAS is a leveraged ETF that seeks daily investment results, before fees and expenses, equal to 300% of the performance of the Financial Select Sector Index. The fund is managed by Direxion and carries a net expense ratio of 0.88%. It uses derivative instruments, including swap agreements, to achieve its daily leveraged objective, and rebalances its exposure at the end of each trading session. Because of daily compounding, returns over periods longer than a single day can diverge significantly from three times the index return.

The underlying index is concentrated in large-cap U.S. financial stocks. As of the most recent data, the portfolio's sector weightings include Financial Services (approximately 29%), Banks (28%), Capital Markets (26%), Insurance (14%), and Consumer Finance (4%). The fund holds roughly 75 to 80 securities, with the top ten positions accounting for more than half of the index. The largest holdings are Berkshire Hathaway Class B, JPMorgan Chase, Visa, Mastercard, Bank of America, Goldman Sachs, Wells Fargo, Citigroup, Morgan Stanley, and American Express. This concentrated exposure to systemically important financial institutions means FAS is highly sensitive to macroeconomic developments, interest rate expectations, and regulatory shifts affecting the financial sector.

Price Performance: +20% Over 30 Days and +27% for the Quarter

Over the last 30 days, FAS climbed from approximately $136 to $163, representing a gain of about 20%. The advance was not linear; the ETF experienced several sharp upward bursts interspersed with brief pullbacks, consistent with the amplified volatility characteristic of a 3x leveraged product. Daily swings of 3% to 5% were common during this period, reflecting both the leverage factor and elevated activity in the underlying financial names. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Looking at the broader quarter, FAS rose roughly 27%, moving from around $128 in early April to current levels near $163. The three-month trend has been predominantly upward, with the most pronounced acceleration occurring in the most recent 30-day window. This pattern suggests that positive sentiment toward financial stocks has been building steadily, with momentum intensifying as the quarter progressed. The quarterly performance underscores a sustained rotation into financials rather than a short-lived tactical bounce.

Drivers Behind the 30-Day Rally in FAS

The 30-day surge in FAS can be attributed primarily to a broad-based rally in U.S. bank and capital markets stocks, which together represent more than half of the underlying index. Large money-center banks and investment banks — including JPMorgan Chase, Bank of America, Goldman Sachs, and Morgan Stanley — posted strong gains, fueled by an improving net interest income outlook and robust capital markets activity. The 3x daily leverage embedded in FAS amplified these individual stock moves, producing an ETF return roughly three times the daily index performance over the period.

Macroeconomic conditions provided additional tailwinds. Resilient economic growth data eased recession concerns, while a steepening yield curve supported bank profitability expectations. Investor sentiment toward the financial sector improved as market participants priced in a more stable interest rate environment. Insurance holdings, including Berkshire Hathaway, also contributed positively. The combination of strong price action in top holdings, favorable sector-level catalysts, and the mechanical effect of daily leveraged compounding drove the approximately 20% advance in FAS over the 30-day window.

Factors Supporting the Quarterly Gain of Roughly 27%

The quarterly gain of approximately 27% reflects a longer-term rotation into financial stocks that began gaining traction in the second quarter of 2026. Several structural factors supported this move. The interest rate environment remained supportive of bank net interest margins, while capital markets revenues benefited from sustained deal-making and trading volumes. Large-cap financial institutions, which dominate the index, reported earnings that generally met or exceeded market expectations, reinforcing confidence in the sector's earnings power.

Institutional flows into financial sector ETFs also played a role. As macroeconomic uncertainty in other sectors persisted, financials attracted capital seeking relative stability and exposure to a higher-rate environment. The performance of credit card networks such as Visa and Mastercard added further support, as consumer spending remained resilient. The cumulative effect of these drivers, magnified by FAS's 3x daily leverage, produced the strong quarterly result.

Using AI Tools for Sector Analysis

When screening for ETFs and stocks showing strong momentum or sector leadership, I find Tickeron's AI Screener helpful as an AI-powered discovery platform. It lets investors scan thousands of securities using technical indicators, fundamental metrics, volatility patterns, AI-generated signals, and industry classifications. The tool helps filter for breakout candidates, trending sectors, and securities matching specific performance characteristics in real time, which can streamline idea generation and market monitoring. Explore the AI Screener to uncover new opportunities aligned with your investment approach.

Outlook: What to Watch for FAS Going Forward

The trajectory of FAS in the coming months will depend heavily on the direction of interest rates, the shape of the yield curve, and the health of the broader economy. Federal Reserve policy decisions and inflation data releases will be critical inputs, as they directly influence bank profitability and capital markets activity. Earnings reports from major index constituents — particularly JPMorgan Chase, Bank of America, and Goldman Sachs — will provide important signals about credit quality, loan growth, and trading revenues.

Regulatory developments, including potential changes to capital requirements, also warrant close attention. Additionally, because FAS is a daily-reset leveraged product, volatility and the path of daily returns will significantly influence cumulative performance. Investors should monitor sector rotation trends, institutional flow data, and macroeconomic indicators to assess whether the current momentum in financials can be sustained. While the recent performance has been strong, leveraged ETFs carry heightened risks and require active management.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: FAS

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


Momentum Indicator for FAS turns positive, indicating new upward trend

FAS saw its Momentum Indicator move above the 0 level on July 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for FAS just turned positive on August 04, 2026. Looking at past instances where FAS's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

The 50-day moving average for FAS moved above the 200-day moving average on July 22, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FAS advanced for three days, in of 352 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 261 cases where FAS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for FAS moved out of overbought territory on August 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FAS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

FAS broke above its upper Bollinger Band on July 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are JPMorgan Chase & Co (NYSE:JPM), VISA (NYSE:V), Mastercard (NYSE:MA), Bank of America Corp (NYSE:BAC), Morgan Stanley (NYSE:MS), Goldman Sachs Group (NYSE:GS), Wells Fargo & Co (NYSE:WFC), American Express Company (NYSE:AXP), Citigroup (NYSE:C), Charles Schwab Corp (The) (NYSE:SCHW).

Industry description

The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the Financials Select Sector Index. The fund invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index includes securities of companies from the following industries: financial services; insurance; banks; capital markets; mortgage real estate investment trusts; and consumer finance. It is non-diversified.

Market Cap

The average market capitalization across the Direxion Daily Financial Bull 3X ETF ETF is 105.6B. The market cap for tickers in the group ranges from 5.72B to 947.12B. JPM holds the highest valuation in this group at 947.12B. The lowest valued company is MKTX at 5.72B.

High and low price notable news

The average weekly price growth across all stocks in the Direxion Daily Financial Bull 3X ETF ETF was 4%. For the same ETF, the average monthly price growth was 8%, and the average quarterly price growth was 14%. ERIE experienced the highest price growth at 9%, while FIS experienced the biggest fall at -7%.

Volume

The average weekly volume growth across all stocks in the Direxion Daily Financial Bull 3X ETF ETF was -19%. For the same stocks of the ETF, the average monthly volume growth was -9% and the average quarterly volume growth was -42%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 61
Price Growth Rating: 34
SMR Rating: 39
Profit Risk Rating: 44
Seasonality Score: -17 (-100 ... +100)
View a ticker or compare two or three
FAS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Trading--Leveraged Equity
Address
Direxion Shares ETF Trust33 Whitehall Street,10th FloorNew York
Phone
866-476-7523
Web
http://www.direxioninvestments.com/
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.